As per reports, the Janssen unit of Johnson & Johnson (JNJ) has sued healthcare giant Amgen Inc as the latter plans to market drugs for ulcerative colitis and conditions similar to J&J’s top-selling drug Stelara. Last year, Stelara generated $9.1 billion of the company’s $52 billion in global drug sales. The drug is approved to treat Crohn’s disease, a related form of arthritis, and the skin condition psoriasis.
A law passed in 2009, allows companies to make biosimilar versions of biologic drugs as a substitute, quite similar to generic versions of conventional drugs. Johnson & Johnson alleged that Amgen has failed to follow the legal process required for the companies to litigate any patent disputes by that law.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work toward finding therapeutic treatments for Breast Cancer.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
